{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:20:53Z","timestamp":1790371253183,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.jaut.2013.12.016","type":"journal-article","created":{"date-parts":[[2014,1,4]],"date-time":"2014-01-04T01:31:19Z","timestamp":1388799079000},"page":"44-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"special_numbering":"C","title":["Central role of interferon-beta in thymic events leading to myasthenia gravis"],"prefix":"10.1016","volume":"52","author":[{"given":"Perrine","family":"Cufi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Dragin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Ruhlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia Miriam","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie","family":"Fadel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Serraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Berrih-Aknin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7522-5974","authenticated-orcid":false,"given":"Rozen","family":"Le Panse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2013.12.016_bib1","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000212371","article-title":"Myasthenia gravis with anti-acetylcholine receptor antibodies","volume":"26","author":"Meriggioli","year":"2009","journal-title":"Front Neurol Neurosci"},{"key":"10.1016\/j.jaut.2013.12.016_bib2","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3109\/08916930903518073","article-title":"The auto-antigen repertoire in myasthenia gravis","volume":"43","author":"Vrolix","year":"2010","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jaut.2013.12.016_bib3","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.imbio.2012.05.006","article-title":"SDF-1\/CXCL12 recruits B cells and antigen-presenting cells to the thymus of autoimmune myasthenia gravis patients","volume":"218","author":"Weiss","year":"2013","journal-title":"Immunobiology"},{"key":"10.1016\/j.jaut.2013.12.016_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/08916930903563491","article-title":"Thymic remodeling associated with hyperplasia in myasthenia gravis","volume":"43","author":"Le Panse","year":"2010","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jaut.2013.12.016_bib5","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.4049\/jimmunol.157.8.3752","article-title":"Expression of acetylcholine receptor genes in human thymic epithelial cells: implications for myasthenia gravis","volume":"157","author":"Wakkach","year":"1996","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaut.2013.12.016_bib6","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1172\/JCI113401","article-title":"Thymus in myasthenia gravis. Isolation of T-lymphocyte lines specific for the nicotinic acetylcholine receptor from thymuses of myasthenic patients","volume":"81","author":"Melms","year":"1988","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jaut.2013.12.016_bib7","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/BF00915728","article-title":"In\u00a0vitro anti-acetylcholine receptor antibody synthesis by myasthenia gravis patient lymphocytes: correlations with thymic histology and thymic epithelial-cell interactions","volume":"7","author":"Safar","year":"1987","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaut.2013.12.016_bib8","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.4049\/jimmunol.145.7.2115","article-title":"Thymic B cells from myasthenia gravis patients are activated B cells. Phenotypic and functional analysis","volume":"145","author":"Leprince","year":"1990","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaut.2013.12.016_bib9","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1371\/journal.ppat.0020062","article-title":"The thymus is a common target organ in infectious diseases","volume":"2","author":"Savino","year":"2006","journal-title":"PLoS Path"},{"key":"10.1016\/j.jaut.2013.12.016_bib10","doi-asserted-by":"crossref","first-page":"7868","DOI":"10.4049\/jimmunol.177.11.7868","article-title":"Microarrays reveal distinct gene signatures in the thymus of seropositive and seronegative Myasthenia Gravis patients and the role of CCL21 in thymic hyperplasia","volume":"177","author":"Le Panse","year":"2006","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaut.2013.12.016_bib11","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1212\/WNL.0b013e3181d7d884","article-title":"Detection of poliovirus-infected macrophages in thymus of patients with myasthenia gravis","volume":"74","author":"Cavalcante","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.jaut.2013.12.016_bib12","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/ana.21902","article-title":"Epstein-Barr virus persistence and reactivation in myasthenia gravis thymus","volume":"67","author":"Cavalcante","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jaut.2013.12.016_bib13","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/ana.23791","article-title":"Implication of double-stranded RNA signaling in the etiology of autoimmune myasthenia gravis","volume":"73","author":"Cufi","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jaut.2013.12.016_bib14","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1136\/jnnp.60.3.348","article-title":"Myasthenia gravis in a patient with chronic active hepatitis C during interferon-alpha treatment","volume":"60","author":"Piccolo","year":"1996","journal-title":"J\u00a0Neurol Neurosurg Psychiatr"},{"key":"10.1016\/j.jaut.2013.12.016_bib15","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1136\/jnnp.60.3.348-a","article-title":"Development of myasthenia gravis during interferon-alpha treatment for anti-HCV positive chronic hepatitis","volume":"60","author":"Mase","year":"1996","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jaut.2013.12.016_bib16","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1136\/jnnp.2003.028233","article-title":"Development of myasthenia gravis in two patients with multiple sclerosis following interferon beta treatment","volume":"75","author":"Dionisiotis","year":"2004","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jaut.2013.12.016_bib17","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1212\/WNL.45.2.382","article-title":"Myasthenia gravis during interferon alfa therapy","volume":"45","author":"Batocchi","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.jaut.2013.12.016_bib18","doi-asserted-by":"crossref","first-page":"5941","DOI":"10.4049\/jimmunol.174.10.5941","article-title":"Effects of cytokines on acetylcholine receptor expression: implications for myasthenia gravis","volume":"174","author":"Po\u00eba-Guyon","year":"2005","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaut.2013.12.016_bib19","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1196\/annals.1405.019","article-title":"Regulatory and pathogenic mechanisms in human autoimmune myasthenia gravis","volume":"1132","author":"Le Panse","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jaut.2013.12.016_bib20","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1046\/j.1365-2249.2003.02113.x","article-title":"Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and\/or myasthenia gravis","volume":"132","author":"Meager","year":"2003","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaut.2013.12.016_bib21","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1210\/jc.2008-0935","article-title":"Autoantibodies against type I interferons as an additional diagnostic criterion for autoimmune polyendocrine syndrome type I","volume":"93","author":"Meloni","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jaut.2013.12.016_bib22","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaut.2013.12.018","article-title":"Thymoma-associated Myasthenia Gravis: on the search for a pathogen signature","volume":"52","author":"Cufi","year":"2014","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.jaut.2013.12.016_bib23","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.0105-2896.2004.00204.x","article-title":"Interferons, interferon-like cytokines, and their receptors","volume":"202","author":"Pestka","year":"2004","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jaut.2013.12.016_bib24","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.immuni.2006.08.010","article-title":"Type I interferon in systemic lupus erythematosus and other autoimmune diseases","volume":"25","author":"Banchereau","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.jaut.2013.12.016_bib25","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.coviro.2011.11.001","article-title":"Induction and function of type I and III interferon in response to viral infection","volume":"1","author":"Levy","year":"2011","journal-title":"Current opinion in virology"},{"key":"10.1016\/j.jaut.2013.12.016_bib26","doi-asserted-by":"crossref","first-page":"e1000017","DOI":"10.1371\/journal.ppat.1000017","article-title":"IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in\u00a0vivo","volume":"4","author":"Sommereyns","year":"2008","journal-title":"PLoS Path"},{"key":"10.1016\/j.jaut.2013.12.016_bib27","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/jid.2010.244","article-title":"Evidence for a pathophysiological role of keratinocyte-derived type III interferon (IFN\u03bb) in cutaneous lupus erythematosus","volume":"131","author":"Zahn","year":"2011","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaut.2013.12.016_bib28","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1182\/blood-2005-06-2383","article-title":"The chemokine CXCL13 is a key molecule in autoimmune Myasthenia Gravis","volume":"108","author":"M\u00e9raouna","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2013.12.016_bib29","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/ana.21628","article-title":"CCL21 overexpressed on lymphatic vessels drives thymic hyperplasia in Myasthenia","volume":"66","author":"Berrih-Aknin","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jaut.2013.12.016_bib30","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jneuroim.2008.06.028","article-title":"Thymus and Myasthenia Gravis: what can we learn from DNA microarrays?","volume":"201-202","author":"Cizeron-Clairac","year":"2008","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.jaut.2013.12.016_bib31","doi-asserted-by":"crossref","first-page":"10872","DOI":"10.1073\/pnas.1934678100","article-title":"Selective contribution of IFN-alpha\/beta signaling to the maturation of dendritic cells induced by double-stranded RNA or viral infection","volume":"100","author":"Honda","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaut.2013.12.016_bib32","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0090-1229(85)90018-2","article-title":"Acetylcholine receptor antibody-producing cells in thymus and lymph nodes in myasthenia gravis","volume":"34","author":"Fujii","year":"1985","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.jaut.2013.12.016_bib33","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.smim.2006.06.002","article-title":"Impact of the BAFF\/BR3 axis on B cell survival, germinal center maintenance and antibody production","volume":"18","author":"Kalled","year":"2006","journal-title":"Semin Immunol"},{"key":"10.1016\/j.jaut.2013.12.016_bib34","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jneuroim.2006.05.023","article-title":"The thymus is a source of B-cell-survival factors-APRIL and BAFF-in myasthenia gravis","volume":"178","author":"Thangarajh","year":"2006","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.jaut.2013.12.016_bib35","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1074\/jbc.M309631200","article-title":"Cells previously desensitized to type 1 interferons display different mechanisms of activation of stat-dependent gene expression from naive cells","volume":"279","author":"Sakamoto","year":"2004","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jaut.2013.12.016_bib36","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/nature06066","article-title":"An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus","volume":"448","author":"Giraud","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.jaut.2013.12.016_bib37","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1084\/jem.20070795","article-title":"Proliferative arrest and rapid turnover of thymic epithelial cells expressing Aire","volume":"204","author":"Gray","year":"2007","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jaut.2013.12.016_bib38","doi-asserted-by":"crossref","first-page":"893","DOI":"10.2353\/ajpath.2007.070240","article-title":"Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status","volume":"171","author":"Leite","year":"2007","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaut.2013.12.016_bib39","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0165-5728(89)90070-2","article-title":"Monoclonal antibodies against the main immunogenic region of the acetylcholine receptor. Mapping on the intact molecule","volume":"23","author":"Kordossi","year":"1989","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.jaut.2013.12.016_bib40","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1046\/j.1365-2249.1997.4701367.x","article-title":"Expression of human-Torpedo hybrid acetylcholine receptor (AChR) for analysing the subunit specificity of antibodies in sera from patients with myasthenia gravis (MG)","volume":"109","author":"Loutrari","year":"1997","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaut.2013.12.016_bib41","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/358155a0","article-title":"Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen","volume":"358","author":"Lehmann","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.jaut.2013.12.016_bib42","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0165-5728(03)00209-1","article-title":"Breakage of tolerance to hidden cytoplasmic epitopes of the acetylcholine receptor in experimental autoimmune myasthenia gravis","volume":"140","author":"Feferman","year":"2003","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.jaut.2013.12.016_bib43","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/00062752-200101000-00010","article-title":"Germinal center reaction","volume":"8","author":"McHeyzer-Williams","year":"2001","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.jaut.2013.12.016_bib44","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1002\/art.21062","article-title":"Association of CXCL13 and CCL21 expression with the progressive organization of lymphoid-like structures in Sjogren's syndrome","volume":"52","author":"Barone","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaut.2013.12.016_bib45","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/intimm\/dxh227","article-title":"IFN{alpha} enhances human B-cell chemotaxis by modulating ligand-induced chemokine receptor signaling and internalization","volume":"17","author":"Badr","year":"2005","journal-title":"Int Immunol"},{"key":"10.1016\/j.jaut.2013.12.016_bib46","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.smim.2006.04.003","article-title":"Regulation of B cell self-tolerance by BAFF","volume":"18","author":"Brink","year":"2006","journal-title":"Semin Immunol"},{"key":"10.1016\/j.jaut.2013.12.016_bib47","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.autrev.2013.03.011","article-title":"Ectopic germinal centers, BAFF and anti-B-cell therapy in myasthenia gravis","volume":"12","author":"Berrih-Aknin","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaut.2013.12.016_bib48","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood-2003-11-3900","article-title":"Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis","volume":"105","author":"Balandina","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2013.12.016_bib49","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jneuroim.2009.02.004","article-title":"Association of HLA-A in autoimmune myasthenia gravis with thymoma","volume":"210","author":"Vandiedonck","year":"2009","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.jaut.2013.12.016_bib50","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ni.2193","article-title":"The thymic epithelial microRNA network elevates the threshold for infection-associated thymic involution via miR-29a mediated suppression of the IFN-alpha receptor","volume":"13","author":"Papadopoulou","year":"2012","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaut.2013.12.016_bib51","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1128\/MCB.00146-10","article-title":"The type I interferon signaling pathway is a target for glucocorticoid inhibition","volume":"30","author":"Flammer","year":"2010","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.jaut.2013.12.016_bib52","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.clim.2012.03.005","article-title":"Emerging therapies for systemic lupus erythematosus\u2013focus on targeting interferon-alpha","volume":"143","author":"Lichtman","year":"2012","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaut.2013.12.016_bib53","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1136\/ard.2010.144485","article-title":"Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study","volume":"70","author":"Merrill","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaut.2013.12.016_bib54","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1002\/art.24557","article-title":"Neutralization of interferon-alpha\/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus","volume":"60","author":"Yao","year":"2009","journal-title":"Arthritis Rheum"}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841113001637?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841113001637?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:08:28Z","timestamp":1760256508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841113001637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":54,"alternative-id":["S0896841113001637"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2013.12.016","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Central role of interferon-beta in thymic events leading to myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2013.12.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}